Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
INBX Inhibrx Biosciences	$23.94 +1.6%	$18.95	$10.81 ▼ $25.29	$346.65M	0.24	105,093 shs	190,063 shs
NTLA Intellia Therapeutics	$10.90 -0.9%	$10.75	$5.90 ▼ $24.16	$1.17B	2.31	4.10 million shs	6.92 million shs
PAHC Phibro Animal Health	$30.57 -1.3%	$27.31	$16.16 ▼ $31.80	$1.24B	0.8	259,350 shs	194,542 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+1.91%
INBX Inhibrx Biosciences	+7.53%	+12.35%	+2.66%	+96.09%	+108.58%
NTLA Intellia Therapeutics	+1.29%	-3.25%	-7.95%	+36.31%	-50.91%
PAHC Phibro Animal Health	+4.31%	+16.87%	-1.84%	+29.92%	+72.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	1.7425 of 5 stars	0.0	1.0	0.0	4.6	2.7	1.7	1.3
NTLA Intellia Therapeutics	4.6083 of 5 stars	4.3	2.0	0.0	4.7	2.9	2.5	0.6
PAHC Phibro Animal Health	4.2083 of 5 stars	0.9	5.0	2.5	1.1	3.3	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
NTLA Intellia Therapeutics	2.58	Moderate Buy	$29.05	166.54% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-20.18% Downside

Current Analyst Ratings Breakdown

Latest INBX, CALT, PAHC, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/11/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $60.00
8/8/2025	NTLA Intellia Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $45.00
8/8/2025	NTLA Intellia Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
8/8/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
INBX Inhibrx Biosciences	$200K	1,733.26	$126.00 per share	0.19	$9.23 per share	2.59
NTLA Intellia Therapeutics	$57.88M	20.22	N/A	N/A	$6.66 per share	1.64
PAHC Phibro Animal Health	$1.02B	1.22	$2.18 per share	14.04	$6.34 per share	4.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
INBX Inhibrx Biosciences	$1.69B	$116.75	0.21	N/A	N/A	N/A	-85.12%	-58.90%	N/A
NTLA Intellia Therapeutics	-$519.02M	-$4.69	N/A	N/A	N/A	-908.48%	-57.48%	-45.04%	N/A
PAHC Phibro Animal Health	$2.42M	$0.78	39.19	14.56	0.50	2.68%	30.51%	6.89%	8/27/2025 (Estimated)

Latest INBX, CALT, PAHC, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	N/A	N/A	N/A	$362.24 million	N/A
8/7/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	-$0.99	+$0.04	-$0.98	$12.26 million	$14.25 million
5/14/2025	Q4 2024	INBX Inhibrx Biosciences	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.57%	N/A	61.54%	N/A

Latest INBX, CALT, PAHC, and NTLA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
INBX Inhibrx Biosciences	1.04	5.12	5.12
NTLA Intellia Therapeutics	N/A	5.19	4.90
PAHC Phibro Animal Health	2.67	2.91	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
INBX Inhibrx Biosciences	82.46%
NTLA Intellia Therapeutics	88.77%
PAHC Phibro Animal Health	99.34%

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
INBX Inhibrx Biosciences	17.09%
NTLA Intellia Therapeutics	3.10%
PAHC Phibro Animal Health	50.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
INBX Inhibrx Biosciences	166	14.48 million	12.00 million	Optionable
NTLA Intellia Therapeutics	600	107.35 million	104.02 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable

INBX, CALT, PAHC, and NTLA Headlines

Recent News About These Companies

Phibro Animal Health Corporation (NASDAQ:PAHC) Shares Sold by Mackenzie Financial Corp

August 11 at 4:35 AM | marketbeat.com

Phibro Animal Health Corp. Financials | PAHC | Barron's

August 10, 2025 | barrons.com

Equities Analysts Offer Predictions for PAHC FY2026 Earnings

August 10, 2025 | americanbankingnews.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Receives Average Rating of "Reduce" from Analysts

August 10, 2025 | americanbankingnews.com

Zacks Research Has Strong Forecast for PAHC FY2026 Earnings

August 9, 2025 | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Given Consensus Rating of "Reduce" by Brokerages

August 5, 2025 | marketbeat.com

PAHC vs. LMAT: Which Stock Should Value Investors Buy Now?

August 4, 2025 | zacks.com

Empirical Financial Services LLC d.b.a. Empirical Wealth Management Makes New Investment in Phibro Animal Health Corporation (NASDAQ:PAHC)

August 4, 2025 | marketbeat.com

15,477 Shares in Phibro Animal Health Corporation (NASDAQ:PAHC) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

August 4, 2025 | marketbeat.com

KLP Kapitalforvaltning AS Has $90,000 Stake in Phibro Animal Health Corporation (NASDAQ:PAHC)

August 1, 2025 | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) to Issue $0.12 Quarterly Dividend

July 30, 2025 | marketbeat.com

Navellier & Associates Inc. Takes Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 27, 2025 | marketbeat.com

Best Growth Stocks to Buy for July 23rd

July 23, 2025 | zacks.com

Best Value Stocks to Buy for July 23rd

July 23, 2025 | zacks.com

Hussman Strategic Advisors Inc. Grows Stock Holdings in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18, 2025 | marketbeat.com

Jackson Creek Investment Advisors LLC Makes New Investment in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18, 2025 | marketbeat.com

Pzena Investment Management LLC Has $15.46 Million Position in Phibro Animal Health Corporation (NASDAQ:PAHC)

July 18, 2025 | marketbeat.com

Phibro Animal Health Corporation (NASDAQ:PAHC) Stock Holdings Trimmed by Teacher Retirement System of Texas

July 18, 2025 | marketbeat.com

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

July 17, 2025 | zacks.com

Best Growth Stocks to Buy for July 17th

July 17, 2025 | zacks.com

3 Reasons Why Growth Investors Shouldn't Overlook Phibro (PAHC)

July 16, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX, CALT, PAHC, and NTLA Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/12/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Inhibrx Biosciences NASDAQ:INBX

$23.94 +0.37 (+1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$23.89 -0.05 (-0.21%)

As of 04:20 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Intellia Therapeutics NASDAQ:NTLA

$10.90 -0.10 (-0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$11.04 +0.14 (+1.24%)

As of 04:27 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$30.57 -0.39 (-1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$30.56 -0.01 (-0.03%)

As of 04:20 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time